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Abstract
Background: One key step in gene expression is the biogenesis of mRNA ribonucleoparticle complexes (mRNPs).
Formation of the mRNP requires the participation of a number of conserved factors such as the THO complex.
THO interacts physically and functionally with the Sub2/UAP56 RNA-dependent ATPase, and the Yra1/REF1/ALY
RNA-binding protein linking transcription, mRNA export and genome integrity. Given the link between genome
instability and cancer, we have performed a comparative analysis of the expression patterns of THOC1, a THO
complex subunit, and ALY in tumor samples.
Methods: The mRNA levels were measured by quantitative real-time PCR and hybridization of a tumor tissue
cDNA array; and the protein levels and distribution by immunostaining of a custom tissue array containing a set of
paraffin-embedded samples of different tumor and normal tissues followed by statistical analysis.
Results: We show that the expression of two mRNP factors, THOC1 and ALY are altered in several tumor tissues.
THOC1 mRNA and protein levels are up-regulated in ovarian and lung tumors and down-regulated in those of
testis and skin, whereas ALY is altered in a wide variety of tumors. In contrast to THOC1, ALY protein is highly
detected in normal proliferative cells, but poorly in high-grade cancers.
Conclusions: These results suggest a differential connection between tumorogenesis and the expression levels of
human THO and ALY. This study opens the possibility of defining mRNP biogenesis factors as putative players in
cell proliferation that could contribute to tumor development.
Background
Gene expression involves multiple processes from tran-
scription to mRNA processing, export and translation.
During transcription, the nascent pre-mRNA associates
with RNA-binding proteins and undergoes a series of
processing steps, resulting in export-competent mRNA
ribonucleoprotein complexes (mRNPs) that are exported
to the cytoplasm [1]. Eukaryotic cells have developed
quality control mechanisms that prevent the export of
suboptimal mRNPs and synthesis of dysfunctional pro-
teins [2]. Aberrant expression of mRNA binding pro-
teins affect different steps of mRNA metabolism,
significantly altering gene expression. The physiological
relevance of mRNP biogenesis control is supported by
the fact that altered expression or dysfunction of some
RNA binding proteins are associated with various
diseases including cancer, as for example that of some
3’-end processing factors and of some proteins involved
in alternative splicing [3,4].
The THO complex is a conserved eukaryotic nuclear
complex that functions in mRNP biogenesis [5]. This
complex was first isolated in Saccharomyces cerevisiae as
a four-protein complex composed of stoichiometric
amounts of Tho2, Hpr1, Mft1, and Thp2 [6]. THO has
also been purified in Drosophila and human cells and
the complexes contain counterparts of the yeast
subunits Hpr1 and Tho2, called Thoc1 and Thoc2
respectively, as well as additional components such as
Thoc5-Thoc7 and hTex1/Thoc3 [7,8]. THO interacts
physically and functionally with proteins involved in
mRNA export: the Sub2/UAP56 RNA-dependent
ATPase, and the Yra1/REF1/ALY RNA-binding protein;
forming a larger complex termed TREX (transcription-
export complex) [8]. Yeast THO, sub2 mutant and to a
lesser extent yra1 mutants show similar phenotypes of
transcription impairment, mRNA export defects and
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transcription-associated hyperrecombination which indi-
cate that these proteins could act in the same mRNP
biogenesis pathway [5,9]. THO and Sub2 can be consid-
ered the closest related factors, given the capacity of
Sub2 overexpression to suppress THO mutations, and
the similarity in the strength of the phenotypes con-
ferred by hpr1, tho2 and sub2 mutations [10,11].
The relevance of THO in cell physiology has been
clearly shown from yeast to humans. Yeast THO null
mutants are sick and slow growers and THO depletion
has a negative effect on growth rate of human and Droso-
phila cell lines [6,7,12]. Moreover, THO is required for
viability of the early mouse embryo and for postnatal sur-
vival, as determined by a THOC1 knockout [13]. A con-
nection of THO with cancer development has also been
suggested. In human, Thoc1 was identified as a nuclear
matrix protein that binds to the retinoblastoma tumor
suppressor protein pRb [14]. High levels of hHPR1/
THOC1 have been observed in breast and lung cancer
cells and are associated with tumor size and aggressive-
ness [12,15]. However, neither the pattern of expression
of THOC1 and other THO components and related pro-
teins in different tumors and the possible mechanism
underlying this process are known. Although, data of
gene expression derived from microarray and systematic
protein localization analyses are available [16,17], little is
known about the expression of these genes in a wide
range of cancers and its relation with the pathologies of
patients. To get further insight into the role of mRNP
biogenesis factors in cancer an analysis was performed of
the expression pattern of THO and other functionally
related factors such as ALY and hSpt4 in different
human tumors. The results showed that both the expres-
sion of THOC1 and ALY is altered in several tumor tis-
sues, suggesting a connection of these mRNP biogenesis
factors with tumorogenesis. A comparative analysis of
the expression pattern of these genes using tissue tumor
arrays reveals differences between them that could be
compatible with a different role in the mRNP biogenesis
and relevance in other biological processes.
Methods
Materials
cDNA probes were obtained by PCR of cDNA clones
purchased from I.M.A.G.E. consortium. Mouse mono-
clonal anti-THOC1 and anti-ALY were purchased from
Abcam, and secondary reagents were purchased from
Dako for immunohistochemistry analysis (IHC).
Cell Lines
Breast cancer cell lines (MCF7, SKBr-3 and T47-D), and
MCF10-A were purchased from American Type Culture
Collection and propagated according to the conditions
recommended by the vendor.
Tissue microarrays
1 mm tissue cores were obtained from archival paraffin
blocks of tumors resected at Hospital Universitario Vir-
gen del Rocío, and then arrayed into recipient paraffin
blocks. Pathological diagnoses are provided in Addi-
tional file 1. The collection and use of the human mate-
rial was approved by the local ethics committee.
Quantitative Real-Time Reverse Trancription-PCR Analysis
Total RNA was isolated from breast cell lines using Pure-
script RNA isolation kit (Gentra System), cDNA was
synthesized with transcriptor first-strand cDNA synthesis
kit (Roche) and Real-time PCR was performed with SYBR
green dye in the 7500 Real Time PCR system of Applied
Biosystems by following the manufacturer’s instructions.
THO-UAP56 and ALY specific primers were designed
using Primer Express software (the sequence is available
upon request). The HPRT1 gene was used as an endogen-
ous control after evaluating different housekeeping genes
in several breast cancer cell lines and identifying HPRT as
the most stable internal control.
Immunohistochemistry for THOC1 and ALY
Immunohistochemical analyses (IHC) were performed
on tissue microarray four-micron sections. Monoclonal
antibodies against THOC1 and ALY were used. Tissues
were microwaved in 1 mM EDTA buffer (for ALY) or
treated with 4N HCl and trypsin for THOC1. Primary
antibody incubation was overnight at 4°C. Secondary
reagents (Dako) were applied according to manufac-
turer’s protocol. Slides were then counterstained with
hematoxylin and mounted in DPX. Sections where the
primary antibody was omitted were used as negative
controls. Immunostaining was evaluated at least on 10
microscopic fields at × 200 by two independent patholo-
gists and unequivocal immunostained cells were
counted. Immunohistochemical expression was scored
as strong (>50% of the carcinoma cells stained), weak
(10%-50%) or negative (<10%). Digital images were
acquired using a Zeiss microscope.
Statistical analysis
A two-tailed paired t-test was used to determine
whether the differences in THOC1, ALY and hSPT4
cDNA levels in tumor versus normal samples were sta-
tistically significant. To determine the association
between the expression levels of ALY with a high grade
tumor, a chi-squared test was performed.
Results
Deregulation of THOC1 and ALY mRNA Expression in
Tumors
First the mRNA levels of THOC1 and ALY in tumor
tissues by hybridization of a Cancer Profiling Array II
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(Clontech) were evaluated. THOC1, was taken as repre-
sentative of factors that act at the transcription level
such as THO-UAP56, and ALY, as a related factor that
serves as adaptor in mRNA export. We also analyzed
the expression of hSpt4, the subunit of the human tran-
scription elongation factor DSIF, [18], which participates
early in transcription and is not related to mRNA
export. The array contains normalized cDNAs from
tumor and matched normal tissues from a variety of
organs (154 cDNAs pair samples derived from 19 differ-
ent tissues and 3 to 11 patients by tissue). The results of
the hybridization and the relative expression in tumor
samples calculated as the ratio of tumor versus normal
signal (T/N) are shown in Figure 1A and Additional
file 2. We considered those cases in which the values of
T/N ratio of cDNAs were outside the interval 0.5-1.5
(Figure 1B). THOC1 was ubiquitously expressed in all
normal tissues (Additional file 2) and a significant
increase was found in ovary, stomach and lung tumors
(marked with *; for more details see Additional file 3)
with the highest levels of overexpression in ovary (4 fold
higher than those of the matched normal samples)
(Figure 1A). In addition, a statistically significant reduc-
tion of THOC1 transcripts was observed in thyroid,
testis and skin tumors, even though in the later the
differences were lower (Figure 1). We have compared
our results with the SAGE (Serial Analyses of Gene
Expression) data of THOC1 available at the human
Gene Compendium GeneCard http://www.genecards.
org. The GeneCard data show changes in THOC1
mRNA levels in tumor versus normal tissues, in almost
all samples analyzed: higher levels in lymphoid node,
breast, lung, colon, liver, pancreas, prostate and skin and
lower in thyroid, cortex and cerebellum. In contrast our
analyses report significant changes in only a subset of
the tissues analyzed, as indicated above.
The expression pattern of ALY was analyzed with the
same cDNA array. Hybridization with an ALY specific
probe revealed a general and strong signal for ALY tran-
scripts in all normal tissues tested, with the highest levels
in testis (Additional file 2). ALY mRNA was increased in
a wide variety of tumors, whereas it was not significantly
reduced in any tissue (Figure 1, Additional file 3). SAGE
analyses show also that ALY mRNA levels are higher in a
number of tissues, except in thyroid and cortex tissues in
which a strong reduction is observed.
Expression of the transcription factor hSPT4 in
tumors was similar to those of normal matched tissues
in almost all the different organs studied (except vulva,
rectum and thyroid).
From the analyses of cDNA arrays we can conclude
that there is a differential pattern of expression of
THOC1 and ALY in tumor tissues. However, given the
number of comparisons made (see Additional file 3), we
cannot discard that in some cases the comparison might
reach the chosen level of significance by random. There-
fore, the analyses of cDNA arrays indicate that THOC1
is differentially expressed in some tumors, both upregu-
lated and downregulated, whereas ALY is overexpressed
in a broad range of tumors and only a few significant
changes were observed for hSPT4.
Up-regulation of THO-UAP56 and ALY expression in
breast cancer cells
It has been described that THOC1 is overexpressed in
breast cancer [12]; however, we only detected 3 out of
10 tumor samples with mRNA levels higher than the
corresponding normal samples. We decided to study in
more detail the expression of THO and other mRNP
factors in breast tissues. We evaluated the expression
of the components of the human THO complex,
THOC1, THOC2, THOC3, THOC5, THOC6 and
THOC7, as well as the expression levels of UAP56 and
ALY in breast cancer cell lines (Figure 2). mRNA levels
were analyzed by real-time-PCR in the malignant
breast tumor cell lines MCF7, SKBr3 and T47-D and
compared to those of the breast immortalized cell line
MCF10-A. An increase in the expression of all compo-
nents of the THO complex was observed in the breast
cancer cell lines, the expression being stronger in
SKBr3 and T47D, the most aggressive of the breast
tumor cell lines analyzed (Figure 2A). Interestingly,
THOC6 mRNA levels were the highest. Although pre-
liminary, these data could indicate that in some cases
the stoichiometry of THO is altered and suggest that
THOC6 could play additional roles apart from the
THO complex [19,20]. RT-PCR of UAP56 and ALY
indicated that these genes were also overexpressed in
breast cancer cell lines. The study was extended by
performing immunostaining analysis of THOC1 and
ALY in normal and tumor breast tissues in order to
see if the protein levels of these factors had also
increased. Specific antibodies were used to immunos-
tain an array containing 43 breast cancer samples and
normal breast controls. A weak signal for THOC1 pro-
tein was detected in the cytoplasm of normal ductal
epithelial cells and a strong nuclear signal in 80% of
the tumor samples analyzed (Figure 2B). Immunohisto-
chemical analysis using anti- ALY revealed a strong
expression of this protein in the nucleus of epithelial
glands in normal breast tissues. This nuclear signal
was observed with at least the same intensity in 70% of
the breast tumor samples analyzed (Figure 2B). Never-
theless, given the high expression levels of the ALY
protein the sensitivity of this array to detect an
increase in ALY expression is limited. These data are
in agreement with the overexpression of hHPR1/
THOC1 previously reported in breast cancer cell lines
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Figure 1 THOC1, ALY and hSPT4 expression in paired normal/tumor tissues by cDNA array. (A) A Cancer Profiling Array II (Clontech),
representing cDNA pools from matched tumor and normal tissue, was hybridized with specific [32P]dCTP-labeled THOC1, ALY and hSPT4 probes,
according to manufacturer’s instructions. cDNA expression values were calculated by quantification of signal intensities in a FUJI FLA 3000. Gene
expression in paired tumor/normal tissues from the same patient was quantified considering expression in normal tissues as one unit. Upper
panel represents the ratio tumor/normal of each pair in the different types of tumors. N, normal; T, tumor. (B) Number of tumors showing
upregulation (T/N > 1.5) or downregulation (T/N < 0.5) of THOC1, ALY and hSPT4 genes. The number is marked in bold in that tissues where
the genes were up- or down-regulated in ≥50% of the tumors analyzed. A two-tailed paired t-test was used to determine whether the
differences in cDNA levels in tumor versus normal samples were statistically significant (marked with *, for details see Additional file 3).
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[12] and could indicate an up-regulation of the expres-
sion of ALY in breast cancer, at least at the mRNA
level.
Comparative analysis of THOC1 and ALY proteins using a
tumor tissue array
Next, we decided to extend the comparative analysis
between THOC1 and ALY, with the analysis by immu-
nostaining of the protein levels and distribution of these
factors in tumor samples (Figure 3 and Figure 4). For
this purpose, a custom tissue array containing a set of
paraffin-embedded samples of different tumor and nor-
mal tissues was created. The array contained a represen-
tation of tumor specimens of those organs in which,
according to the results of the analysis of the cDNA
tumor array, THOC1 and ALY could be expected to be
deregulated. It was done with a total of 121 samples
including approximately 3 normal tissue controls and an
average of 9 samples covering low and high-grade
tumors for each organ analyzed (for more details see
Additional file 1). As can be seen in Figure 3, THOC1
staining revealed that the gene was expressed in all nor-
mal tissues with the highest expression in skin and pan-
creas. The lower signal was detected in stomach,
bladder and testis, and the weakest staining was
observed in ovary, colon, lung and thyroid. An increase
in THOC1 protein signal in the nucleus was detected
in ovarian, colon and lung tumors (Figure 3A and 3B).
Our results suggest that THOC1 could be relevant in
ovarian tumors, in which THOC1 expression levels were
high in almost all the carcinomas analyzed (Figure 3A
and Figure 1). The increase in the expression of THOC1
protein has been confirmed by western blot in some
ovarian and lung normal and tumor samples (Additional
file 4). A loss of THOC1 protein staining was observed
in testis and skin cancers, in up to 75% of the samples.
In these tumors the nuclear signal disappeared and a
low immunoreactivity was detected in the cytoplasm
(Figure 3). In general, the protein data, although IHC is
not a real quantitative method, is in agreement with the
results obtained by hybridization of the cDNA array in
all these tissues, except for stomach and thyroid tumors
that showed a protein signal very similar to that of nor-
mal samples.
Tissue microarrays provide the possibility to immuno-
histochemically stain a large number and variety of nor-
mal and cancer tissues, as it is the case of the human
protein atlas [17]. We have compared our IHC results
with those obtained in the human protein atlas. In the
case of THOC1 the comparison does not provide reli-
able results, because there are two protein atlas IHC
analyses (HPA019687 and HPA019096) with different
conclusions due to the different protein levels detected
in the tissues samples. Whereas in the first few cases of
Figure 2 Expression of THO-UAP56 and ALY in breast tumor
cell lines. (A) mRNA levels of THOC1, THOC2, THOC3, THOC5,
THOC7, UAP56 and ALY were determined by real-time quantitative
PCR (RT-PCR) in breast tumor cell lines MCF7, SKBr3 and T47-D and
compared to those of the non tumor cell line MCF10-A. Data are
representative of two independent experiments, and quantitative
PCRs were repeated three times for each one. Errors bars show
standard deviation (SD). (B) Immunohistochemical analysis of
THOC1 and ALY expression in normal breast tissues and breast
carcinomas. Immunohistochemical analysis was performed on
formalin-fixed, paraffin-embedded specimens (see Table below).
After incubation with antibodies the slides were counterstained
with hematoxylin. Bars represent 50 μm. Expression levels of THOC1
and ALY were determined in a semi-quantitative way (negative
staining; weak staining and strong nuclear positivity, for more
details see Materials and Methods). In the upper panel a
representative photograph of normal and tumor tissue is shown. At
the bottom negative controls with no primary antibody are
included. Inserts show details at higher magnification. The results of
the immunohistochemical analysis of 43 samples are summarized in
the table below.
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Figure 3 Immunohistochemical analysis of THOC1 in normal and tumor tissues. A series of tumors and normal samples from different
tissues was tested by immunohistochemistry using surgical paraffin-embedded samples. Tumors were classified as low-grade and high-grade
(pathological diagnoses are detailed in Additional file 1). (A) Results of the semi-quantitative analysis of the inmunohistochemistry of THOC1 are
shown. (B) Figures correspond to representative inmunohistochemical analysis of normal and tumor samples. Bars represent 50 μm. For other
details see Figure 2. THOC1 is weakly expressed in the cytoplasm and nuclei of normal ovarian, colon and lung, and it is intensively expressed in
the nucleus of ovarian, colon and lung carcinoma samples. THOC1 protein levels are reduced in skin and testis tumors: a strong signal is
detected in the epidermis of normal skin and germ cells of normal testis, whereas skin tumors and seminomas show a negative or weaker
cytoplasmic staining.
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breast cancer, malignant lymphomas and melanomas
were considered moderately positive, in the second, this
was only the case in few cases of lung, stomach, pan-
creatic and testicular tumors. On the other hand, the
THOC1 overexpression that we report in breast and
lung tumors is in agreement with the protein atlas data
and other previous studies [12,15]. In contrast to the
atlas IHC data, we observe THOC1 overexpression in
ovarian tumors and a decrease in THOC1 expression in
testis and skin tumor tissues (Figure 3 and Figure 1).
Altogether, these results strengthen the importance of
additional studies to establish a reliable association with
tumorogenicity and THO expression.
Immunohistochemical analyses were performed with
specific antibody anti-ALY, (Figure 4), a strong nuclear
signal for the ALY protein being detected in almost all
the normal tissues, in contrast to the tissue differential
THOC1 immunostaining.
Figure 4 Immunohistochemical analysis of ALY in normal and tumor tissues. (A) Results of the semi-quantitative analysis of the
inmunohistochemistry of ALY are shown. (B) Figures correspond to representative inmunohistochemical analysis of normal and tumor samples.
Bars represent 50 μm. For other details see Figure 3. ALY protein levels are intensively detected in the nuclei of normal and low-grade tumors of
colon, stomach, thyroid and pancreas, whereas some of more advanced tumors such as colon and stomach present a decrease of the nuclear
staining.
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Interestingly, ALY signal was shown to have an equal
intensity in half of the tumor samples as in normal tis-
sues (in 46 out of 94 tumors) (Figure 4A and Table 1).
The intensity of the immunostaining with anti-ALY was
reduced in colon, stomach, thyroid, testis and pancreas
tumor samples with a cytoplasmic and lower signal than
the control samples in almost 50% of the tumors ana-
lyzed (Figure 4B).
When we compare our ALY IHC array with those of
the protein atlas IHC data (reports CAB016281 and
HPA019799, which show close to 90% of coincidence),
it becomes evident that whereas the Protein Atlas shows
that ALY is highly expressed in normal tissues and in a
wide range of tumors, in our study half of the tumors
showed a lower overall signal and an additional cyto-
plasmic distribution (Figure 4A and Table 1).
The ALY protein is poorly detected in high-grade tumors,
but highly detected in normal proliferative cells
A priori, the reduction of the ALY protein contrasts with
the up-regulation of ALY mRNA observed after hybridiza-
tion of the cDNA array (Figure 1). However, when the
ALY protein signal was analyzed in the different tumors, it
was clear that a significant reduction of ALY protein levels
occurs only in the high-grade tumors (a weak or negative
staining in 35% of low-grade tumors -20 out of 58- versus
72% -26 out of 36- in high-grade tumors) (Figure 4A and
Table 1). This datum suggests that ALY protein levels are
down-regulated in the most dedifferentiated phases of the
tumor. The ALY protein atlas IHC data shows that only a
small proportion of tumor samples (13-23%) had a lower
signal than normal tissues and do not provide sufficient
data to make conclusions on the relationship between
ALY expression and tumor grade.
To gain further insight into the physiological relevance
of this reduction, ALY expression was analyzed in differ-
ent normal tissues with high cell proliferation rate or
cells that differentiate into a wide variety of cell types.
As is shown in Figure 5, a strong nuclear signal corre-
sponding to the ALY protein was detected in cells of
the trophoblast in a normal placenta, in the basal
epithelium and lymphoid follicles of normal tonsil and
in the germinal cells of testis. A positive signal was
observed in dividing cells consistent with the high
expression observed in the cDNA array.
Discussion
Our results indicate that disturbed THOC1 and ALY
expression are associated with tumorogenesis. Overex-
pression of THOC1 has previously been correlated to
the grade of invasiveness in breast tumor, and also a
relationship between the levels of this protein in non-
small lung cancers has been suggested [12,15]. This
study shows that not only the expression of THOC1,
but also that of THO/TREX complex is upregulated in
breast cancer cells. Moreover, new links between the
expression of THOC1 and different tumors were found.
THOC1 mRNA and protein levels are up-regulated in
ovarian, and lung tumors and down-regulated in those
of testis and skin. Interestingly, we show that ALY,
another mRNP biogenesis factor is highly detected in
proliferative cells and overexpressed in a broad range of
tumors. The different pattern of expression of THOC1
and ALY in tumors could indicate a different relevance
for each factor in tumorogenesis. Nevertheless, since
many genes are differentially expressed in cancer tissues
and cancerous cell populations are highly heteroge-
neous, any intent of associating a specific expression
profile with tumorogenesis needs further studies and
confirmations with additional tumor banks [16].
Our data indicates that overexpression of THOC1 and
ALY is specifically associated with tumors, and not a con-
sequence of high metabolism and proliferation of tumor
cells, since an altered pattern of expression of transcrip-
tion factors, such as hSpt4 in the cDNA tumor array, was
not observed. At the same time, the different expression
pattern of THOC1, as representative of THO, and ALY
in normal and tumor tissues, indicates a different rele-
vance of these factors in the tumorogenisis process. In
fact, altered expression or dysfunction of other RNA
binding proteins involved in different pre-mRNA meta-
bolic steps such as splicing, 3’-end formation are impli-
cated in various diseases including cancer, supporting the
physiological relevance of mRNP biogenesis control [3].
High levels of the THOC1 protein were observed in the
nuclei of ovarian, and lung cancer tumors in comparison
with normal tissues. As a reduction of THOC1 was also
associated with some cancers such as those of skin and
Table 1 Inmunohistochemical analysis of ALY protein
samples which staining intensity is weaker than normal/total
tumor samples specified
TUMORS all
tumors
low-grade
tumors
high-grade
tumors
ovary 0/8 0/5 0/3
colon 9/15 4/7 5/8
stomach 9/15 4/9 5/6
lung 1/7 1/5 0/2
bladder 3/9 0/6 3/3
thyroid 11/16 4/9 7/7
testis 5/9 2/6 3/3
skin 3/8 1/6 2/2
pancreas 5/7 4/5 1/2
TOTAL
NUMBER
46/94 20/58 26/36
Comparison of ALY staining in low-grade and high-grade tumor populations.
Association of high-grade tumors and weaker staining of ALY protein was
analysed by c2 test ( P value = 0.0004).
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testis, these results argue against the idea that THOC1
expression would be required for proliferation and survi-
val of oncogene-transformed cells [21]. As THO has a
role in mRNP biogenesis, likely general among eukar-
yotes, it is possible that changes in THOC1 expression
could affect mRNP formation as previously reported in
yeast [9,22]. However, we cannot exclude that the pattern
of expression of THOC1 in some tumors could also be
related to a specific physiological role of THO in differ-
ent tissues. It is not clear yet whether the physiological
relevance is the same in the different tissues and at differ-
ent stages of development and differentiation. In this
sense, it has recently been shown that THOC1 condi-
tional knockout mice affects testis development [23], and
that THOC5 function is critical in bone marrow and
hematopoiesis [24]. Therefore THOC1 expression levels
might potentially be used as a prognostic indicator in
specific tumors, but not a general biomarker.
We provide evidence that high expression levels of
ALY are connected to normal proliferative tissues and
with a wide variety of tumors. This is in agreement with
the proposed role of ALY in cell cycle progression and
proliferation [25]. It has been suggested that ALY could
be a physiological target of nuclear PI3K signaling,
which regulates ALY’s subnuclear residency in speckles,
as well as, cell proliferation and mRNA export activities
through nuclear Akt phosphorylation and phosphoinosi-
tide association [25]. Despite this link between mRNA
export function and proliferation, other activities of
ALY could contribute to tumorogenesis. Thus, ALY has
also been proposed as a transcriptional coactivator
important for c-myc expression in virally induced leuke-
mias and lymphomas [26], and the yeast homolog Yra1
has been shown to be required for S phase entry [27].
It is particularly interesting that high ALY mRNA
levels are found in tumor tissues (see cDNA arrays
results), whereas low ALY protein levels are associated
with high-grade tumors. It is possible that a post-
transcriptional regulation of ALY protein occurs in
advanced steps of tumorogenesis. Indeed, ALY is
regulated by the AKT kinase, and inhibition of ALY
phosphorylation substantially decreases cell proliferation
and mRNA export [25]. Interestingly, other proteins
involved in mRNA export, such as the yeast THOC1
ortholog Hpr1, have been shown to be a target of
ubiquitination [28] and phosphorylation [29].
Interestingly, the expression profile of ALY seems to be
similar to that of other related mRNP-export factors, such
as UAP56/Sub2 and NXF1/Mex67, which interact physi-
cally and functionally with THO. Human protein atlas
IHCs for these factors (CAB034012 and CAB016327)
show that normal tissues display a strong nuclear signal
and tumor cells exhibited moderate to strong nuclear
immunoreactivity. Instead, approximately 40% and 65% of
the tumor samples showed a lower staining than the nor-
mal tissues in the UAP56 and NXF1 IHC reports respec-
tively. The significant association between altered ALY
expression and tumors open the possibility that ALY
could be considered as a possible tumor prognostic
marker.
We can conclude that an alteration in THOC1 and
ALY expression is associated with tumorogenesis. Given
the small size of samples available it is possible that for
some tests a sizeable true effect may not have been
detected in this study, which could explain some of the
apparent inconsistencies with other studies. However,
the different patterns of expression of the proteins in
tumors could indicate a different relevance of each
Figure 5 Detection of ALY in normal proliferative cells. Strong
immunostaining of (A) trophoblast of normal placenta
(B) epithelium and lymphoid follicles of normal tonsil, with details
of follicle center cells (insert) (C) germ cells of normal testis. Bars
represent 50 μm (A,C) and 100 μm (B).
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factor in tumorogenesis. Importantly, however, their dif-
ferent pattern of expression would be consistent with a
different functional role of these proteins in mRNP bio-
genesis and export. Despite the physical and functional
interactions between these factors, THO behaves as a
stable structural core in eukaryotic cells [5]. In fact,
Sub2/UAP56 and Yra1/ALY have not been found or are
only detected in substoichiometric amounts in chroma-
tography purifications of the THO complex under high
salt conditions from yeast, Drosophila and human cell
extracts [6,7,12]. ALY is not stably associated with
THO, and this interaction is mediated by UAP56 and
THOC5 [30,19]. Moreover, although ALY/Yra1 recruit-
ment to chromatin was first shown to be dependent on
THO and UAP56/Sub2 factors in yeast [31], other fac-
tors such as the cap-binding protein CBP80 and the
transcription elongation factor Spt6 also contribute to
the cotranscriptional loading of ALY protein [32,33]. It
seems, therefore, that Yra1/ALY could serve as a bridge
between RNA-binding proteins early during mRNP bio-
genesis, acting upstream during transcription and down-
stream at mRNA export. The different pattern of
expression of THO and ALY in tumors is consistent
with a differentiated role of both factors in gene expres-
sion, for the correct proliferation of the cell and devel-
opmental changes that could take place in tumors.
Conclusion
These results suggest a differential connection between
tumorogenesis and the expression levels of human THO
and ALY mRNP biogenesis factors. Our study opens the
possibility of defining mRNP biogenesis factors as puta-
tive players in cell proliferation and differentiation that
could contribute to tumor development.
Additional material
Additional file 1: Brief description of the pathological diagnoses
from the tumor samples included in the tissue array. The table
shows a brief description of the pathological diagnoses.
Additional file 2: Results of hybridization of the cDNA array. The
figure shows the results of hybridization of the cDNA array. THOC1 and
ALY are ubiquitously expressed in all normal tissues. The highest THOC1
mRNA levels are observed in thyroid and liver and the lowest in stomach
and ovary. ALY probe revealed a similar expression in all normal tissues,
with the highest levels in testis.
Additional file 3: Expression of THOC1, ALY and SPT4 determined
by hybridization of a Cancer Profiling array with THOC1, ALY and
SPT4 probes. In the table, it is shown the average of intensity (LAU/
mm2) found for the THOC1, ALY or SPT4 hybridization probes in normal
tissues (N) or tumor tissues (T) and its corresponding statistical error
mean (St. error mean). Results were analyzed by using the two-tailed t-
test which compares two paired groups by means of calculating the
difference between each set of pairs, and which is based on the
assumption that the differences in the entire population follow a
Gaussian distribution. Samples marked in grey were found to be
statistically significant (p < 0.05).
Additional file 4: THOC1 expression in Ovary and Lung tumors. A)
Western blot of THOC1 and b actin (as endogenous control) in ovary
and lung tissues. B) THOC1 mRNA relative expression in ovary and lung
tissues measured by RT-PCR.
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